
Advertise on podcast: Few & Far Between: How Biotech Gets Built
Rating
5from
This podcast has
35 episodes
Language
EnglishPublisher
Chris O'BrienExplicit
No
Date created
2021/06/09
Latest episode
2026/01/27
Average duration
49 min.
Release period
18 days
Description
Welcome to Few & Far Between! Chris O'Brien, CEO of Biorasi, is your host for fascinating conversations - from clinical research and policymakers to biotech innovators and industry leaders.
Unlock Few & Far Between: How Biotech Gets Built podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from Few & Far Between: How Biotech Gets Built podcast
Video Episode 68: Sinan Gölhan, CEO at GelTech Labs
2026/01/27
How do today’s CEOs and founders find the balance between planning and entrepreneurship?
Check out the latest episode of the Biorasi Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes Sinan Gölhan, CEO at GelTech Labs. We'll be exploring life in a biotech startup, hydrogels in lab robotics, and bringing AI into your organization.
Watch this episode today!
Video Episode 67: Aoife Brennan, President and CEO of Climb Bio
2026/01/07
Let's kick off 2026 with the first Biorasi podcast episode of the year!
How do you get "Biotech Vision" to see the complete picture of your place in the industry?
Find out in the latest episode of the Few & Far Between podcast - How Biotech Gets Built. Host Chris O'Brien welcomes guest Aoife Brennan, President and CEO of Climb Bio. We'll be discussing how to leverage science and strategy, the differences between CEOs and CMOs, and how hiring an "operational penknife" is critical to new organizations.
Watch it today!
Episode 66: Mark Abelson, Founder of Ora Clinical
2025/12/16
Are clinical trial protocols a true art form?
Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder of Ora Clinical and CRO pioneer.
We'll be discussing exploratory endpoints, what to learn from failed trails, and essential factors in choosing a clinical site location.
Listen today!
Video Episode 65 - Amit Etkin, Founder and CEO of Alto Neuroscience
2025/11/24
With biotech, is it the destination, the journey, or both?
Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etkin, Founder and CEO of Alto Neuroscience and Professor of Psychiatry at Stanford University School of Medicine. We’ll be discussing placebos in psychiatry, using biomarkers for patient outcomes, and what you can and can’t do in academia and biotech.
Watch it today!
Video Episode 64 - Professor Justin Stebbing
2025/11/11
Will GLP-1's one day replace our morning coffee?
Find out in a special video episode of the Few & Far Between podcast!
Host Chris O'Brien welcomes friend of the show, Professor Justin Stebbing. In this new segment, we'll spotlight biotech trends that you need to know about - from T cells to GLP-1 - and identify which innovations are worth the hype.
Let's start the podcast!
Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences
2025/10/28
What if the future of biotech is actually late-stage execution?
Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien. Today, we welcome guest Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences. We’ll be covering a myriad of biotech topics, from “business athletes” to the role of the operating company in the drug development industry. We’ll also be premiering our lightning round - quick questions and inspired answers from our podcast guests.
Okay, let’s start the podcast!
Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology
2025/10/22
When is the right time for a biotech to bring in a Chief Marketing Officer/CMO?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology. Listen in as we access the marketer inside each of us, discuss how knowing people might be more important than business and finance, and follow the steps to maintain the fine balance between marketing and reality.
Let's start the podcast!
Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics
2025/10/01
Why is a feather-light touch important in fighting infections?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody Bryan, President and CEO of Revolo Biotherapeutics. Tune in as we press the reset button on the human immune system, explore upstream and downstream levers for treating autoimmune diseases, and how to stay competitive in the biotech industry.
Let's start the podcast!
Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech
2025/09/17
Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast.
Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Get ready for part two of this special two-part episode as we touch on smarter LLMs, evolved AI agents, and connecting data to real-world biology.
Okay, let's start the podcast!
Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech
2025/09/03
What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast.
Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at Anima Biotech, to the podcast. Tune in to part one of this special two-part episode as we double-click on #AIagents, building neural networks, and syncing visual biology with real-world biology.
Okay, let's start the podcast!
Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences
2025/08/14
How does a biopharma background prepare you for the biotech playground?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jerry McLaughlin, CEO and Board Member at Life Biosciences, for an insightful discussion on cellular rejuvenation, working hand in hand with a board of directors, and knowing when to walk away from a clinical trial.
Tune in today!
Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation
2025/07/22
Is the epigenome the "software" of the cell nucleus?
Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, President and CEO of DURECT Corporation, for a conversation on the importance of a pharmacoeconomic strategy, developing new treatments for alcohol associated hepatitis, and moving beyond what a single individual can do in clinical research.
Tune in today!
Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics
2025/07/15
How do experienced troubleshooters solve a difficult problem? By asking the right questions first!
Welcome back to part two of our conversation with Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics. Join host Chris O'Brien as he and Dr. Tolentino, explore the traits of top problem solvers, the power of communication, and how silos and "bad apples" can undermine today's biotechs.
Okay, let's start the podcast!
Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®
2025/07/09
How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region.
In our latest episode of the Biorasi Few & Far Between podcast, host Chris O'Brien welcomes Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®. Tune in as we spotlight the advantages of running studies in #LATAM - from data quality to speed to approval.
Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics
2025/05/28
The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast.
Host Chris O'Brien welcomes Michael Tolentino, MD, Co-Founder and Head Scientific Consultant at Aviceda Therapeutics, to the podcast. Tune in to part one of this special two-part episode as we explore Michael's start in ophthalmology, groundbreaking treatments in intra-retinal therapy, and the importance of being a great communicator.
Okay, let's start the podcast!
Podcast reviews
Read Few & Far Between: How Biotech Gets Built podcast reviews
Rob from Raleigh 2025/01/13
Very Informative!
Love listening to all of the great guests. Chris is a fantastic host and brings guests with unique perspectives to explore the world of biopharma.
ChristopherOB 2021/06/16
Diverse & interesting
Diverse and interesting interviews with people from across the rare disease drug development world.
Podcast sponsorship advertising
Start advertising on Few & Far Between: How Biotech Gets Built relevant audience podcasts
You may also like to advertise on these Podcasts

4.8696459
All In with Allie
Allie Reeves

4.1697977
Deep Energy Podcast - Music for Sleep, Meditation, Yoga, Background Music and Studying
Jim Butler

4.5253501
Locked On Bucs – Daily Podcast On The Tampa Bay Buccaneers
Locked On Podcast Network, James Yarcho

5218368
The Ken Harbaugh Show
MeidasTouch Network

4.515733757
Guys We F****d
Corinne Fisher and Krystyna Hutchinson

4.6185564
The Tara Show
Audacy

4.71242000
The Gooner Talk
The Gooner Talk

4.93614593
Ask a Cycling Coach Podcast - Presented by TrainerRoad
TrainerRoad

4.4267545
The Joe Rose Show
Audacy

4.5358547
BMitch & Finlay
Audacy